← Leaderboards
Cyril Barinka
Georgetown University
$792,791
Attributed
$2,378,374
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $618.6K · FY2021–24$1M$750K$500K$250K$0
'21
'22
'23
'24
Funding mix
By agency
NIH$2,378,374 · 1
By mechanism
R01$2,378,374 · 1
Top collaborators
- Alejandro V Villagra5 shared
- Duncan John Wardrop5 shared
Most similar at Georgetown University
Same institution · by research overlap
- Alejandro V Villagra$1,948,655
- Duncan John Wardrop$3,076,392
- Anton Wellstein$12,396,274
- Sarah Martinez Roth$100,677
- Hyang-Sook Hoe$548,936
Others in their field
Other Emerging Leaders on “Cytotoxic”
- Stacey Lynn Clardy · Utah State Higher Education System--University Of Utah$15,093,619
- John Damon Chodera · Sloan-Kettering Inst Can Research$15,076,495
- Wilton B Williams · Duke University$11,406,665
- Deanna A Kulpa · Emory University$10,394,989
- Elizabeth Fox · St. Jude Children'S Research Hospital$8,840,232
- Mara Becker · Duke University$6,798,777
Research focus
CytotoxicAdvanced Malignant NeoplasmAnti-Inflammatory AgentsAdjuvantAnti-Pd-1Anti-Tumor Immune ResponseAttentionAutoimmunityAntineoplastic AgentsBlocking AntibodiesCancer CellCancer ImmunotherapyCancer TherapyCardiacCd8b1 GeneCellsCell TherapyCharacteristicsChronicCombination ImmunotherapyCombined Modality TherapyCtla4 GeneCytokineCytotoxic Agent
Grant awards (5)
Development of selective HDAC6 inhibitors to improve cancer immunotherapy$567,683
R01 · FY2024 · CA
Development of selective HDAC6 inhibitors to improve cancer immunotherapy$605,710
R01 · FY2023 · CA
Development of selective HDAC6 inhibitors to improve cancer immunotherapy$514,297
R01 · FY2022 · CA
Development of selective HDAC6 inhibitors to improve cancer immunotherapy$104,326
R01 · FY2022 · CA
Development of selective HDAC6 inhibitors to improve cancer immunotherapy$586,358
R01 · FY2021 · CA